Stephen Palmer

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 16

Top Topics

Health Information

Systematic Review

Neoadjuvant Chemotherapy

Top Venues

Journal of medical economics

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics 27 (1) (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics (2024)
Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo. Journal of medical economics (2024)
Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y Patel, Tayla Poretta, Ronac Mamtani, Stephen Palmer
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of medical economics 27 (1) (2024)
Ana Duarte, Mark S Corbett, Hollie Melton, Melissa Harden, Stephen Palmer, Marta O Soares, Mark Simmonds
EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (49) (2022)
Ana Duarte, Mark S Corbett, Hollie Melton, Melissa Harden, Stephen Palmer, Marta O Soares, Mark Simmonds
EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (49) (2022)
Ana Duarte, Mark S Corbett, Hollie Melton, Melissa Harden, Stephen Palmer, Marta O Soares, Mark Simmonds
EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (49) (2022)
Peter Murphy, David Glynn, Sofia Dias, Robert Hodgson, Lindsay Claxton, Lucy Beresford, Katy Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso, Kath Wright, Anna Cantrell, Matthew D Stevenson, Stephen Palmer
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health technology assessment (Winchester, England) 25 (76) (2022)
Ana Duarte, Mark S Corbett, Hollie Melton, Melissa Harden, Stephen Palmer, Marta O Soares, Mark Simmonds
EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (49) (2022)
Ana Duarte, Mark S Corbett, Hollie Melton, Melissa Harden, Stephen Palmer, Marta O Soares, Mark Simmonds
EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation. Health technology assessment (Winchester, England) 26 (49) (2022)
Mark Rodgers, David Marshall, Mark Simmonds, Ann Le Couteur, Mousumi Biswas, Kath Wright, Dheeraj Rai, Stephen Palmer, Lesley A Stewart, Robert Hodgson
Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England) 24 (35) (2021)
Mark S Corbett, Ana Duarte, Alexis Llewellyn, James Altunkaya, Melissa Harden, Martine A Harris, Simon M Walker, Stephen Palmer, Sofia Dias, Marta O Soares
Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation. Health technology assessment (Winchester, England) 24 (39) (2021)